Adicet bio appoints dr. blake aftab as vice president of research

Menlo park, calif. and boston, april 13, 2021 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer and other diseases, today announced the appointment of blake aftab, ph.d., as vice president of research. dr. aftab will lead adicet's research group and will further develop existing and new opportunities for the company's gamma delta t cell platform.
ACET Ratings Summary
ACET Quant Ranking